Table 2.
Proportion of patients with a clinically meaningful response, based on funding source: Only studies with clear public or industry funding were analyzed. Those with unclear funding sources were not included in the analysis.
| TREATMENT TYPE | RCTS | INDUSTRY FUNDING | INTERVENTION EVENT RATE, % (N/N) | CONTROL EVENT RATE, % (N/N) | RISK RATIO (95% CI) | NNT | P VALUE* |
|---|---|---|---|---|---|---|---|
| Exercise | 0 | Industry funding | NA† | NA† | NA† | NA† | NA† |
| 10 | Clearly publicly funded | 47 (332/703) | 22 (136/634) | 2.38 (1.78–3.18) | 4 | ||
| Intra-articular corticosteroids | 3 | Industry funding | 50 (129/257) | 44 (68/155) | 1.15 (0.85–1.55) | NSS | .05 |
| 3 | Clearly publicly funded | 49 (46/94) | 17 (14/82) | 2.66 (1.22–5.77) | 4 | ||
| SNRIs (duloxetine only) | 6 | Industry funding | 64 (655/1030) | 43 (443/1030) | 1.53 (1.25–1.87) | 5 | NA† |
| 0 | Clearly publicly funded | NA† | NA† | NA† | NA† | ||
| NSAIDs (oral) | 39 | Industry funding | 57 (11 785/20 810) | 39 (2560/6518) | 1.42 (1.34–1.50) | 6 | .008 |
| 1 | Clearly publicly funded | 67 (214/318) | 57 (178/313) | 1.18 (1.05–1.34) | 10 | ||
| Glucosamine | 6 | Industry funding | 41 (176/425) | 25 (105/423) | 1.62 (1.28–2.05) | 7 | .006 |
| 3 | Clearly publicly funded | 52 (208/399) | 51 (201/396) | 0.99 (0.76–1.28) | NSS | ||
| NSAIDs (topical) | 14 | Industry funding | 56 (1594/2847) | 48 (1354/2808) | 1.19 (1.09–1.31) | 13 | NA† |
| 0 | Clearly publicly funded | NA† | NA† | NA† | NA† | ||
| Chondroitin | 8 | Industry funding | 54 (505/932) | 41 (375/914) | 1.30 (1.14–1.49) | 8 | .10 |
| 1 | Clearly publicly funded | 64 (202/318) | 57 (178/313) | 1.12 (0.98–1.27) | NSS | ||
| Viscosupplementation | 23 | Industry funding | 54 (1502/2805) | 45 (1137/2555) | 1.20 (1.10–1.32) | 12 | .72 |
| 1 | Clearly publicly funded | 36 (30/84) | 32 (27/84) | 1.11 (0.73–1.70) | NSS | ||
| Opioids (oral) | 14 | Industry funding | 46 (1740/3743) | 43 (992/2293) | 1.17 (1.02–1.34) | 32 | NA† |
| 0 | Clearly publicly funded | NA† | NA† | NA† | NA† | ||
| Acetaminophen | 2 | Industry funding | 47 (240/513) | 43 (204/478) | 1.17 (0.83–1.64) | NSS | NA† |
| 0 | Clearly publicly funded | NA† | NA† | NA† | NA† |
NA—not applicable, NNT—number needed to treat, NSAID—nonsteroidal anti-inflammatory drug, NSS—not statistically significant, RCT—randomized controlled trial, SNRI—serotonin-norepinephrine reuptake inhibitor.
*
P value for testing between subgroup differences.
†
Not applicable, as one subgroup was not present.